Wick Capital Partners’s AstraZeneca AZN Stock Holding History

Wick Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$721K	Buy	3,658 +45	+1%	+$8.68K	0.13%	68
2025 Q4	$664K	Buy	3,613 +10	+0.3%	+$1.75K	0.12%	71
2025 Q3	$553K	Sell	3,603 -7,387	-67%	-$1.12M	0.13%	72
2025 Q2	$503K	Buy	10,990 +7,347	+202%	+$1.03M	0.13%	70
2025 Q1	$535K	Sell	3,643 -343	-9%	-$49.6K	0.16%	63
2024 Q4	$522K	Sell	3,986 -31	-0.8%	-$4.34K	0.15%	61
2024 Q3	$626K	Hold	4,017	–	–	0.2%	48
2024 Q2	$626K	Sell	4,017 -284	-7%	-$42.7K	0.22%	44
2024 Q1	$583K	Hold	4,301	–	–	0.57%	22
2023 Q4	$579K	Sell	4,301 -9	-0.2%	-$1.17K	0.24%	38
2023 Q3	$584K	Sell	4,310 -8	-0.2%	-$1.09K	0.33%	35
2023 Q2	$618K	Buy	4,318 +16	+0.4%	+$2.35K	0.37%	27
2023 Q1	$597K	Sell	4,302 -90	-2%	-$12.1K	0.34%	33
2022 Q4	$595K	Buy	4,392 +140	+3%	+$17.6K	0.33%	31
2022 Q3	$466K	Sell	4,252 -191	-4%	-$24.2K	0.3%	31
2022 Q2	$587K	Buy	+4,443	New	+$583K	0.41%	23

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Wick Capital Partners's AZN Position: Q1 2026 in Review

Wick Capital Partners increased its AstraZeneca (AZN) stake by 1.2% in Q1 2026, buying an estimated $8.68K and bringing the position to 3,658 shares worth $721K. The position accounts for 0.13% of the portfolio, ranked #68.

Wick Capital Partners first reported a position in AZN in Q2 2022 and has held it in 16 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Wick Capital Partners held 3,658 shares of AstraZeneca worth $721K as of Q1 2026.
Wick Capital Partners bought 45 AstraZeneca shares in Q1 2026, an estimated $8.68K.
AstraZeneca made up 0.13% of Wick Capital Partners's portfolio in Q1 2026, its #68 holding.
Wick Capital Partners first reported a position in AstraZeneca in Q2 2022 and has held it in 16 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Wick Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.